Top 5 Stocks to Buy Now
→ 25-Cent Gold Explorer Set to Drill Top Canadian Mineral Belt (From Resource Stock Digest) (Ad)tc pixel
NASDAQ:DXR

Daxor Q2 2025 Earnings Report

Daxor logo
$10.14 +0.64 (+6.74%)
As of 06/23/2026 03:27 PM Eastern
ProfileEarnings HistoryForecast

Daxor EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Daxor Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Daxor Announcement Details

Quarter
Q2 2025
Date
3/2/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Daxor's Q2 2026 earnings is estimated for Thursday, August 20, 2026, based on past reporting schedules

Conference Call Resources

Daxor Earnings Headlines

Daxor (NASDAQ:DXR) Trading Up 6.7% - Here's Why
June 24 at 2:20 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30857561
Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
June 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305113/0/en/daxor-corporation-receives-u-s-patent-for-breakthrough-remote-blood-volume-monitor.html
Four winners over 400%. Here's #5
CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highlander Silver before 741%, and Orogen Royalty before 416%. He also publicly predicted Newmont's 126% gain in 2025. Now Goggin says the 1974 petrodollar agreement between Washington and Riyadh has quietly expired, central banks are buying gold at the fastest pace since 1950, and a major monetary shift is underway. He has identified four specific positions - plus two bonus opportunities for readers.tc pixel
June 24 at 1:00 AM  |  Golden Portfolio (Ad)
Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis
April 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/daxor-leverages-medaxiom-cv-transforum-spring-26-to-accelerate-commercial-adoption-of-blood-volume-analysis-1036071514
Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282545/0/en/daxor-leverages-medaxiom-cv-transforum-spring-26-to-accelerate-commercial-adoption-of-blood-volume-analysis.html
Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
April 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/08/3270056/0/en/daxor-expands-customer-footprint-with-new-bva-program-at-high-volume-ohio-cardiology-center.html
See More Daxor Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Daxor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daxor and other key companies, straight to your email.

About Daxor

Daxor (NASDAQ:DXR) is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting. The company offers training and technical support to hospital laboratories and specialty clinics, ensuring that staff are properly instructed in isotope handling, system operation and result interpretation. Through ongoing research collaborations, Daxor continuously evaluates new protocols and software enhancements to improve diagnostic performance and workflow efficiency.

Headquartered in New York, Daxor serves healthcare providers in North America and has established distribution partnerships in Europe, Asia‐Pacific and select emerging markets. Its solutions are used by major university medical centers, community hospitals and research institutions to inform decisions on blood transfusion, fluid management and therapeutic intervention. The company’s management team brings decades of experience in medical technology commercialization, regulatory affairs and laboratory operations, positioning Daxor to expand its global footprint and address evolving needs in patient blood management.

View Daxor Profile
Earnings Tools